Seven Fleet Capital Management
Latest statistics and disclosures from Seven Fleet Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Cg Oncology, TNGX, RVMD, TYRA, LQDA, and represent 41.37% of Seven Fleet Capital Management's stock portfolio.
- Added to shares of these 10 stocks: Cg Oncology (+$97M), IPSC (+$6.7M), Tango Therapeutics (+$6.3M), AGIO (+$6.0M), TNGX (+$6.0M), Avalo Therapeutics (+$5.4M), Minerva Neurosciences (+$5.4M), PCVX, TYRA, Pharvaris N V.
- Started 58 new stock positions in Liquidia Corporation, DFTX, Dianthus Therapeutics, REPL, DNLI, NERV, ROIV, NTLA, SABS, CRVS.
- Reduced shares in these 10 stocks: CGON (-$97M), TERN (-$5.3M), , COGT, BLTE, DYN, , NUVL, ZURA, PRAX.
- Sold out of its positions in ALXO, ACRS, FOLD, Astria Therapeutics, BLTE, CDTX, DYN, ELDN, ENTA, EXEL.
- Seven Fleet Capital Management was a net buyer of stock by $121M.
- Seven Fleet Capital Management has $315M in assets under management (AUM), dropping by 113.24%.
- Central Index Key (CIK): 0002092021
Tip: Access up to 7 years of quarterly data
Positions held by Seven Fleet Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Seven Fleet Capital Management
Seven Fleet Capital Management holds 114 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cg Oncology | 30.9 | $97M | NEW | 1.4M | 67.68 |
|
| Tango Therapeutics (TNGX) | 3.3 | $11M | +133% | 502k | 20.92 |
|
| Revolution Medicines (RVMD) | 2.5 | $7.9M | +22% | 81k | 97.25 |
|
| Tyra Biosciences (TYRA) | 2.4 | $7.5M | +145% | 196k | 38.30 |
|
| Liquidia Corporation Com New (LQDA) | 2.3 | $7.1M | +105% | 188k | 37.74 |
|
| Agios Pharmaceuticals (AGIO) | 2.2 | $7.1M | +560% | 210k | 33.83 |
|
| Century Therapeutics (IPSC) | 2.1 | $6.7M | NEW | 2.9M | 2.26 |
|
| Enliven Therapeutics (ELVN) | 2.0 | $6.4M | +64% | 164k | 39.20 |
|
| Vaxcyte (PCVX) | 2.0 | $6.3M | +327% | 109k | 58.11 |
|
| Tango Therapeutics | 2.0 | $6.3M | NEW | 301k | 20.92 |
|
| Cogent Biosciences (COGT) | 1.8 | $5.8M | -30% | 149k | 38.49 |
|
| Avalo Therapeutics Com New | 1.7 | $5.4M | NEW | 360k | 14.93 |
|
| Minerva Neurosciences Com New | 1.7 | $5.4M | NEW | 889k | 6.03 |
|
| Cg Oncology (CGON) | 1.6 | $5.1M | -94% | 76k | 67.68 |
|
| Pharvaris N V (PHVS) | 1.5 | $4.9M | +212% | 173k | 28.25 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.5 | $4.8M | +218% | 43k | 111.35 |
|
| Dianthus Therapeutics (DNTH) | 1.4 | $4.6M | +270% | 54k | 83.92 |
|
| Pharvaris N V | 1.3 | $4.1M | NEW | 144k | 28.25 |
|
| Cytokinetics Com New (CYTK) | 1.3 | $4.0M | +492% | 61k | 65.91 |
|
| Soleno Therapeutics (SLNO) | 1.2 | $3.9M | -11% | 116k | 33.48 |
|
| Enliven Therapeutics | 1.2 | $3.7M | NEW | 95k | 39.20 |
|
| Erasca (ERAS) | 1.1 | $3.6M | NEW | 223k | 16.18 |
|
| Roivant Sciences SHS (ROIV) | 1.1 | $3.6M | NEW | 128k | 27.70 |
|
| Cytomx Therapeutics | 1.1 | $3.4M | NEW | 714k | 4.70 |
|
| Avalo Therapeutics Com New (AVTX) | 1.0 | $3.2M | +237% | 214k | 14.93 |
|
| Eupraxia Pharmaceuticals (EPRX) | 1.0 | $3.1M | NEW | 434k | 7.24 |
|
| Ideaya Biosciences (IDYA) | 0.9 | $2.9M | NEW | 86k | 33.32 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.9 | $2.8M | +274% | 626k | 4.47 |
|
| Ascendis Pharma A/s Sponsored Ads (ASND) | 0.9 | $2.8M | +114% | 12k | 228.73 |
|
| Compass Therapeutics (CMPX) | 0.9 | $2.7M | -9% | 517k | 5.29 |
|
| Damora Therapeutics Com New (DMRA) | 0.8 | $2.6M | NEW | 101k | 25.90 |
|
| Kalvista Pharmaceuticals (KALV) | 0.8 | $2.6M | +165% | 129k | 20.13 |
|
| Relay Therapeutics (RLAY) | 0.8 | $2.6M | +253% | 258k | 9.95 |
|
| Axsome Therapeutics (AXSM) | 0.8 | $2.4M | +8% | 14k | 169.02 |
|
| Compass Therapeutics | 0.7 | $2.2M | NEW | 424k | 5.29 |
|
| Dianthus Therapeutics | 0.7 | $2.2M | NEW | 27k | 83.92 |
|
| Eupraxia Pharmaceuticals | 0.6 | $2.0M | NEW | 276k | 7.24 |
|
| Definium Therapeutics Com Shs (DFTX) | 0.6 | $1.9M | NEW | 100k | 18.90 |
|
| Mineralys Therapeutics (MLYS) | 0.6 | $1.9M | +65% | 70k | 27.09 |
|
| Soleno Therapeutics | 0.6 | $1.8M | NEW | 54k | 33.48 |
|
| Madrigal Pharmaceuticals (MDGL) | 0.6 | $1.8M | +82% | 3.4k | 523.47 |
|
| Cytomx Therapeutics (CTMX) | 0.6 | $1.7M | +659% | 371k | 4.70 |
|
| Athira Pharma (LONA) | 0.5 | $1.7M | +28% | 165k | 10.28 |
|
| Savara (SVRA) | 0.5 | $1.6M | +371% | 296k | 5.46 |
|
| Perspective Therapeutics Com New (CATX) | 0.5 | $1.6M | NEW | 379k | 4.17 |
|
| Assembly Biosciences Com New (ASMB) | 0.5 | $1.6M | -23% | 56k | 27.75 |
|
| Sab Biotherapeutics Com New | 0.5 | $1.5M | NEW | 400k | 3.83 |
|
| Minerva Neurosciences Com New (NERV) | 0.5 | $1.5M | NEW | 249k | 6.03 |
|
| Zai Lab Adr (ZLAB) | 0.5 | $1.5M | NEW | 78k | 18.81 |
|
| Tarsus Pharmaceuticals (TARS) | 0.4 | $1.4M | +340% | 20k | 70.15 |
|
| Corvus Pharmaceuticals (CRVS) | 0.4 | $1.2M | NEW | 83k | 14.63 |
|
| Vaxcyte | 0.4 | $1.2M | NEW | 20k | 58.11 |
|
| Arrivent Biopharma (AVBP) | 0.4 | $1.2M | NEW | 50k | 23.07 |
|
| Larimar Therapeutics (LRMR) | 0.4 | $1.2M | NEW | 257k | 4.50 |
|
| Krystal Biotech (KRYS) | 0.4 | $1.1M | +7% | 4.3k | 258.32 |
|
| Inventiva Sa Ads (IVA) | 0.4 | $1.1M | NEW | 200k | 5.55 |
|
| Lipocine Com New (LPCN) | 0.3 | $998k | NEW | 125k | 7.99 |
|
| Spyre Therapeutics Com New (SYRE) | 0.3 | $993k | NEW | 20k | 50.44 |
|
| BioCryst Pharmaceuticals (BCRX) | 0.3 | $976k | NEW | 103k | 9.52 |
|
| Xencor (XNCR) | 0.3 | $965k | -26% | 80k | 12.06 |
|
| Celldex Therapeutics Com New (CLDX) | 0.3 | $929k | NEW | 29k | 31.72 |
|
| Replimune Group (REPL) | 0.3 | $921k | NEW | 120k | 7.65 |
|
| Maze Therapeatics (MAZE) | 0.3 | $917k | NEW | 31k | 29.85 |
|
| Eliem Therapeutics (CLYM) | 0.3 | $895k | +71% | 131k | 6.85 |
|
| Compass Pathways Sponsored Ads (CMPS) | 0.3 | $874k | +295% | 158k | 5.53 |
|
| Alkermes SHS (ALKS) | 0.3 | $855k | NEW | 24k | 35.36 |
|
| Silence Therapeutics Ads (SLN) | 0.3 | $826k | +6% | 157k | 5.27 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 0.3 | $805k | +50% | 86k | 9.39 |
|
| Celcuity (CELC) | 0.2 | $685k | -28% | 6.0k | 114.14 |
|
| An2 Therapeutics (ANTX) | 0.2 | $683k | NEW | 200k | 3.42 |
|
| Denali Therapeutics (DNLI) | 0.2 | $678k | NEW | 35k | 19.20 |
|
| United Therapeutics Corporation (UTHR) | 0.2 | $669k | -13% | 1.1k | 592.98 |
|
| Eli Lilly & Co. (LLY) | 0.2 | $662k | NEW | 720.00 | 919.77 |
|
| Verastem Com New (VSTM) | 0.2 | $654k | +715% | 123k | 5.30 |
|
| Liquidia Corporation Com New | 0.2 | $642k | NEW | 17k | 37.74 |
|
| Geron Corporation (GERN) | 0.2 | $632k | -45% | 424k | 1.49 |
|
| Ocuphire Pharma (IRD) | 0.2 | $611k | NEW | 134k | 4.55 |
|
| Inhibikase Therapeutics Com New (IKT) | 0.2 | $547k | -38% | 326k | 1.68 |
|
| Context Therapeutics (CNTX) | 0.2 | $500k | NEW | 191k | 2.62 |
|
| Bright Minds Biosciences Com New (DRUG) | 0.1 | $467k | NEW | 6.4k | 72.97 |
|
| Voyager Therapeutics (VYGR) | 0.1 | $445k | NEW | 115k | 3.86 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.1 | $434k | NEW | 9.0k | 48.20 |
|
| Protagonist Therapeutics (PTGX) | 0.1 | $422k | -50% | 4.0k | 105.40 |
|
| Prothena Corp SHS (PRTA) | 0.1 | $421k | 43k | 9.72 |
|
|
| Intellia Therapeutics (NTLA) | 0.1 | $404k | NEW | 32k | 12.82 |
|
| Milestone Pharmaceuticals (MIST) | 0.1 | $397k | NEW | 333k | 1.19 |
|
| Sab Biotherapeutics Com New (SABS) | 0.1 | $383k | NEW | 100k | 3.83 |
|
| Palisade Bio (PALI) | 0.1 | $373k | -34% | 213k | 1.75 |
|
| Monte Rosa Therapeutics (GLUE) | 0.1 | $371k | +463% | 23k | 16.45 |
|
| Edgewise Therapeutics (EWTX) | 0.1 | $369k | +485% | 12k | 31.50 |
|
| Unicycive Therapeutics Com New (UNCY) | 0.1 | $367k | NEW | 56k | 6.58 |
|
| Contineum Therapeutics Cl A (CTNM) | 0.1 | $353k | NEW | 27k | 13.06 |
|
| Trevi Therapeutics (TRVI) | 0.1 | $324k | +281% | 27k | 11.93 |
|
| Evolus (EOLS) | 0.1 | $321k | -4% | 78k | 4.11 |
|
| Nektar Therapeutics Com New (NKTR) | 0.1 | $309k | -71% | 4.3k | 71.95 |
|
| Fulcrum Therapeutics (FULC) | 0.1 | $292k | NEW | 38k | 7.67 |
|
| Septerna (SEPN) | 0.1 | $275k | 11k | 24.03 |
|
|
| Ocular Therapeutix (OCUL) | 0.1 | $265k | +83% | 31k | 8.47 |
|
| Zentalis Pharmaceuticals (ZNTL) | 0.1 | $257k | NEW | 110k | 2.34 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.1 | $232k | +44% | 17k | 13.90 |
|
| Entera Bio SHS (ENTX) | 0.1 | $228k | +51% | 206k | 1.11 |
|
| Nuvalent Inc-a (NUVL) | 0.1 | $212k | -83% | 2.1k | 102.45 |
|
| Beam Therapeutics (BEAM) | 0.1 | $210k | -7% | 8.8k | 23.83 |
|
| Disc Medicine (IRON) | 0.1 | $207k | NEW | 3.2k | 63.94 |
|
| Aadi Bioscience (WHWK) | 0.1 | $187k | NEW | 54k | 3.45 |
|
| Inhibrx Biosciences (INBX) | 0.1 | $167k | NEW | 2.5k | 67.23 |
|
| Apogee Therapeutics (APGE) | 0.1 | $166k | +9% | 2.0k | 84.17 |
|
| C4 Therapeutics Com Stk (CCCC) | 0.0 | $150k | NEW | 57k | 2.63 |
|
| Promis Neurosciences Com Shs (PMN) | 0.0 | $135k | NEW | 11k | 12.70 |
|
| Tyra Biosciences | 0.0 | $111k | NEW | 2.9k | 38.30 |
|
| Pepgen (PEPG) | 0.0 | $105k | NEW | 60k | 1.77 |
|
| Pmv Pharmaceuticals (PMVP) | 0.0 | $79k | 64k | 1.24 |
|
|
| Macrogenics (MGNX) | 0.0 | $39k | NEW | 13k | 2.89 |
|
| Cullinan Oncology (CGEM) | 0.0 | $26k | -38% | 1.8k | 14.21 |
|
Past Filings by Seven Fleet Capital Management
SEC 13F filings are viewable for Seven Fleet Capital Management going back to 2025
- Seven Fleet Capital Management 2026 Q1 filed May 15, 2026
- Seven Fleet Capital Management 2025 Q4 restated filed April 2, 2026
- Seven Fleet Capital Management 2025 Q4 filed Feb. 26, 2026